OBJECTIVES: To evaluate the costs and benefits of Yindanxintai dropping pills (Guizhou Junzhitang Pharmaceutical Company) for angina pectoris caused by coronary heart disease from the societal perspective. METHODS: The comparator was chosen from published literature. Treatment results and costs were derived from published literature and government websites. A contingent valuation survey was used to elicit the respondents’ willingness-to-pay (WTP) for angina pectoris treatments. The WTP was modeled as a function of the treatment outcomes, design of questionnaire scenarios, individual health states and characteristics. A total of 351 questionnaires were completed. The primary outcome was the annual net cost-benefit or incremental net cost-benefit per person tested. RESULTS: WTP increased with the growth of effective rate. The average WTP was given 377 RMB per month (range 100 RMB to 2000 RMB) to the treatment with a 95% effective rate. There were 7 papers that provided adequate information to the further cost-benefit analysis (CBA). Results from the CBA indicated that Yindanxintai dropping pills had a positive annual net benefit when used alone, and the treatment with 56 days was superior to 28 days with an annual incremental net benefit (AINB) of 4529 RMB per person tested. Yindanxintai dropping pills used with nitroglycerin tablets (Shanghai Sina Pharmaceutical Company) had greater net benefit than simvastatin tablets (Yangtze River Pharmaceutical Group) with nitroglycerin tablets (AINB=1471 RMB). Yindanxintai dropping pills used with isosorbide mononitrate sustained release tablets (AstraZeneca AB), Xinkang tablets (Lunan Pharmaceutical Company), or Xinkang tablets and Xinke tablets (Guangzhou Nanxin Pharmaceutical Company) also had greater net benefit than the other drugs used alone (AINB were 306 RMB, 479 RMB, 1067 RMB, respectively). The results of this research were proved robust through sensitivity analyses. CONCLUSIONS: Yindanxintai dropping pills is cost-beneficial in the treatment of angina pectoris caused by coronary heart disease either used alone or used with other drugs.